logo-loader
Netscientific PLC

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack

cancer cell
The article was published online earlier this month and will be in next month’s print edition of Journal of Immunology

A peer-reviewed publication has given backing to a cancer immunotherapy platform developed by PDS Biotechnology Corporation (NASDAQ:PDSB) – one of Netscientific PLC’s (LON:NSCI) portfolio companies.

The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.

READ: Netscientific soars as it sells stakes in Vortex and Wanda

T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.

A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.

Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.

Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.5 m
Follow

Watch

'Pivotal' moment for NetScientific's Glycotest Inc with $10mln financing

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), spoke to Proactive London's Andrew Scott as their portfolio company Glycotest Inc agreed on terms of a funding round. The US$10mln Series A financing round is with Shanghai Fosun Pharmaceutical, a leading healthcare group...

on 22/10/18

2 min read

;